Alpha Tau Medical (DRTS) Cash & Equivalents (2020 - 2026)

Alpha Tau Medical has reported Cash & Equivalents for 7 years, with the latest figure at $4.6 million in Q1 2026.

• Quarterly Cash & Equivalents fell 7.63% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (down 7.63% YoY) and the FY2025 annual result came in at $12.2 million, down 11.09% from the prior year.
• Cash & Equivalents retreated to $4.6 million in Q1 2026 per DRTS's latest filing, from $12.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $98.9 million in Q1 2022 and troughed at $82000.0 in Q3 2023.
• A 5-year average of $12.0 million and a median of $5.8 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 99.09% in 2023, then jumped 6639.02% in 2024.
• Over 5 years, Cash & Equivalents stood at $5.8 million in 2022, then soared by 116.88% to $12.7 million in 2023, then advanced by 8.43% to $13.7 million in 2024, then declined by 11.09% to $12.2 million in 2025, then tumbled by 62.01% to $4.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $4.6 million, $12.2 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.